A Reuters report dated November 12 says the FDA has effectively shelved the Commissioner’s National Priority Voucher (CNPV) pilot, launched in 2025 under former commissioner Marty Makary to shorten some drug reviews to one or two months.
No new vouchers have reportedly been issued since Makary left in May. The political-appointee executive council overseeing the initiative has gone dormant, and sources say new applications are not progressing even though submissions remain open.
The pilot issued vouchers to 22 drugs; 12 have since been approved. Reuters reported that, for several, the program shortened approval timelines by eight months or more. Career FDA staff are reportedly handling timelines for the remaining participants.
It is not formally confirmed as terminated:
HHS says the pilot is ongoing while the FDA reviews public feedback and considers refinements. So “dead” is a fair description of its apparent current status, but the agency disputes that it has ended.
Sources:
EXCLUSIVE: US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
FDA Shutters Makary's Priority Voucher Program: Reuters
US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
FDA appears to pause controversial speedy review program, complete response letter disclosures
FDA Shelves Priority Voucher Pilot, Stalling Fast-Track Drug Reviews | Pharmaceutical Technology
FDA shelves priority voucher program for faster drug reviews
FDA's Makary-era priority voucher scheme appears to be winding down: report
FDA Shelves Fast-Track Drug Review Initiative
FDA shelves fast-track drug reviews
Exclusive-US FDA shelves commissioner’s voucher program for speedy drug reviews, sources say
Exclusive-US FDA shelves commissioner's voucher program for speedy drug reviews, sources say
FDA's commissioner voucher program reportedly shuttered ...